We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market.
However, many of its key products are facing generic competition. Nevertheless, products like Trajenta, Cialis, Forteo, Strattera, Erbitux, and the animal health segment should help partially offset the impact of genericization. The company also has some new products in its portfolio which should start contributing to revenues.
LLY’s earnings track record has been pretty good with the company delivering positive earnings in three of the last four quarters with an average surprise of 9.42%.
Currently, LLY has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: LLY topped on second quarter earnings by a penny. The company reported EPS of 86 cents while our consensus called for EPS of 85 cents.
Revenue Beat: Revenues also topped expectations. Lilly posted revenues of $5.4 billion, compared to our consensus estimate of $5.1 billion.
Maintains 2016 Outlook: LLY continues to expect 2016 revenues of $20.6 - $21.1 billion and earnings of $3.50 - $3.60 per share. The Zacks Consensus Estimate for earnings and revenues is $3.56 per share and $20.91 billion, respectively.
Updates Long-Term Outlook: Lilly provided updated financial expectations through the remainder of the decade – the company expects at least 5% average annual revenue growth driven by volume, along with higher gross margin, both on a constant currency basis. Lilly also intends to return to annual dividend increases for shareholders and reiterated its commitment to achieve an OPEX-to-revenue ratio of 50% or less in 2018.
Check back later for our full write up on this LLY earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Tops on Q2 Earnings & Revenues
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market.
However, many of its key products are facing generic competition. Nevertheless, products like Trajenta, Cialis, Forteo, Strattera, Erbitux, and the animal health segment should help partially offset the impact of genericization. The company also has some new products in its portfolio which should start contributing to revenues.
LLY’s earnings track record has been pretty good with the company delivering positive earnings in three of the last four quarters with an average surprise of 9.42%.
Currently, LLY has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: LLY topped on second quarter earnings by a penny. The company reported EPS of 86 cents while our consensus called for EPS of 85 cents.
Revenue Beat: Revenues also topped expectations. Lilly posted revenues of $5.4 billion, compared to our consensus estimate of $5.1 billion.
Maintains 2016 Outlook: LLY continues to expect 2016 revenues of $20.6 - $21.1 billion and earnings of $3.50 - $3.60 per share. The Zacks Consensus Estimate for earnings and revenues is $3.56 per share and $20.91 billion, respectively.
Updates Long-Term Outlook: Lilly provided updated financial expectations through the remainder of the decade – the company expects at least 5% average annual revenue growth driven by volume, along with higher gross margin, both on a constant currency basis. Lilly also intends to return to annual dividend increases for shareholders and reiterated its commitment to achieve an OPEX-to-revenue ratio of 50% or less in 2018.
LILLY ELI & CO Price
LILLY ELI & CO Price | LILLY ELI & CO Quote
Check back later for our full write up on this LLY earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>